Servier has entered into a collaborative study with Harvard University researchers to explore a new avenue for the treatment of type 2 diabetes and non-alcoholic fatty liver disease (NAFLD).    Servier and Harvard researchers will embark on a three-year preclinical research project where the ultimate objective is to develop therapeutics targeting the microbiota for the treatment of type 2 diabetes and NAFLD. The work will be conducted by a multidisciplinary team of researchers from both partie...